amisulpride

Amisulpride is a second-generation (atypical) antipsychotic drug belonging to the benzamide class. It is primarily used for the treatment of schizophrenia and has also been approved in some countries for the treatment of dysthymia (persistent mild depression). The drug acts as a selective antagonist at dopamine D2 and D3 receptors. At low doses it preferentially blocks presynaptic dopamine autoreceptors leading to increased dopaminergic transmission in certain brain regions; at higher doses it blocks postsynaptic receptors. This dual action allows amisulpride to improve both positive and negative symptoms of schizophrenia[1][4][7]. It was developed by Sanofi-Aventis and introduced in the 1990s. Its patent expired in 2008.

Brand names

SolianAmiprideSulamid

Other names

氨磺必利阿米舒必利AminosultoprideAmisulpridaAmisulpridum